Journal article

Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer

Pik-Fang Kho, Frederic Amant, Daniela Annibali, Katie Ashton, John Attia, Paul L Auer, Matthias W Beckmann, Amanda Black, Louise Brinton, Daniel D Buchanan, Stephen J Chanock, Chu Chen, Maxine M Chen, Timothy HT Cheng, Linda S Cook, Marta Crous-Bous, Kamila Czene, Immaculata De Vivo, Joe Dennis, Thilo Doerk Show all

INTERNATIONAL JOURNAL OF CANCER | WILEY | Published : 2020

Abstract

Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two-sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low-density lipoprotein [LDL] and high-density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels (P < 5 × 10-8 ) were identified as instrumental variables, and assesse..

View full abstract

Grants

Awarded by Swedish Cancer Society


Awarded by Swedish Labor Market Insurance


Awarded by Stockholm County Council


Awarded by Karolinska Institutet


Awarded by National Cancer Institute of United States Public Health Service


Awarded by Cancer Council Tasmania


Awarded by Cancer Council Queensland


Awarded by National Cancer Institute


Awarded by US Department of Health and Human Services


Awarded by Wellcome Trust Case Control Consortium (WTCCC)


Awarded by NHMRC Senior Research Fellowship


Awarded by NHMRC Early Career Fellowship


Awarded by Australian Government Research Training Program PhD Scholarship


Awarded by QIMR Berghofer Postgraduate Top-Up Scholarship


Awarded by Cancer UK Grant


Awarded by Genome Canada


Awarded by US National Institutes of Health


Awarded by Canadian Institutes of Health Research (CIHR)


Awarded by US Department of Defence


Awarded by National Institutes of Health


Awarded by Cancer Research UK


Awarded by European Community's Seventh Framework Programme


Awarded by National Health and Medical Research Council (NHMRC)


Awarded by NIH


Awarded by Post-Cancer GWAS initiative


Funding Acknowledgements

Australian National Health and Medical Research Council; VicHealth and Cancer Council Victoria; Fred Hutchinson Cancer Research Center; Susan G. Komen Breast Cancer Foundation; Agency for Science, Technology and Research of Singapore (A*STAR); The Swedish Cancer Society, Grant/Award Number: 11 0439; The Swedish Labor Market Insurance, Grant/Award Number: 100069; Stockholm County Council and Karolinska Institutet, Grant/Award Numbers: DF 07015, 20110141, 20110483, 20110222; Haukeland University Hospital; The Research Council of Norway; The Norwegian Cancer Society; Melzer Foundation; Helse Vest Grant; Mayo Foundation; Fred C and Katherine B Andersen Foundation; National Cancer Institute of United States Public Health Service, Grant/Award Numbers: P50 CA136393, P30 CA15083, R01 CA122443; Verelst Foundation; Rudolf Bartling Foundation; ELAN fund of the University of Erlangen; Cancer Council Tasmania, Grant/Award Numbers: ID#457636, ID#403031; The Cancer Council Queensland, Grant/Award Number: ID#4196615; National Cancer Institute, Grant/Award Number: U19 CA148065-01; US Department of Health and Human Services, Grant/Award Numbers: HHSN271201100004C, HHSN268201100004C, HHSN268201100003C, HHSN268201100002C, HHSN268201100001C, HHSN268201100046C; National Heart, Lung, and Blood Institute; Wellcome Trust Case Control Consortium (WTCCC), Grant/Award Numbers: 090532/Z/09Z, 085475, 068545/Z/02; NHMRC Senior Research Fellowship, Grant/Award Number: APP1061779; NHMRC Early Career Fellowship, Grant/Award Number: APP1111246; Australian Government Research Training Program PhD Scholarship and QIMR Berghofer Postgraduate Top-Up Scholarship, Grant/Award Numbers: 1074383, 396414, 209057; Cancer UK Grant, Grant/Award Number: C1287/A16563; NIH Grant, Grant/Award Numbers: R01 CA77398, R01 CA91019, 2R01 CA082838, CA128008, CA54281, KO5 CA92002, R35 CA39779, NO1 HD23166, RO3 CA80636, RO1 CA75977, RO1 CA 87538, RO1 CA105212, 1R01 CA134958, R01 CA49449, P01 CA087969, UM1 CA186107, U19 CA148065; Genome Canada Grant, Grant/Award Number: GPH-129344; US National Institutes of Health, Grant/Award Numbers: R01-CA058598, R01-CA149429, U19-CA148112, CA1X01HG007491-01; Ovarian Cancer Research Fund; Breast Cancer Research Foundation; Canadian Institutes of Health Research (CIHR), Grant/Award Number: MOP-86727; US Department of Defence, Grant/Award Number: W81XWH-10-1-0341; Post-Cancer GWAS initiative, Grant/Award Numbers: 1U19 CA148112, 1U19 CA148065, 1U19 CA148537; the National Institutes of Health, Grant/Award Number: CA128978; Cancer Research UK, Grant/Award Numbers: C490/A10124, C8197/A16565, C5047/A10692, C5047/A15007, C5047/A8384, C1281/A12014, C12292/A11174, C1287/A10710, C1287/A10118; European Community's Seventh Framework Programme, Grant/Award Number: 223175; National Health and Medical Research Council (NHMRC), Grant/Award Numbers: ID#339435, G0000934, ID#1031333, ID#552402, ID#1109286